Challenges and opportunities

Leading data, scientific, and pharmaceutical experts discuss the current challenges in drug discovery and potential opportunities to improve the process.

Hexagon shaped overlay
Close-up of transparent spherical capsules illuminated in blue, each containing intricate, embedded structures resembling cells or circuits.

Can AI assist synthetic biology for new drug development?

Nathan Lanclos and Graham Hudson, Ph.D., and from the University of California, Berkeley, Keasling Lab and the Joint BioEnergy Institute (JBEI)
Read interview

How do predictive models empower drug discovery?

Adam Sanford, Ph.D., and Orr Ravitz, Ph.D., from CAS
Read interview

How can prioritizing data accelerate drug discovery?

Zoheb Hassan, Ph.D., from Frost & Sullivan
Read interview

Can we expand therapies by reaching for undruggable targets?

Mauro Mileni, Ph.D., and Chris Roth, Ph.D., from Abilita Therapeutics
Read interview

Why are new authority constructs necessary for life sciences data?

Nicole Stobart, Jeff Wilson, Ph.D., and Mark Schmidt from CAS
Read interview

How well do models predict protein functions?

Iddo Friedberg, Ph.D., from Iowa State University
Read interview

Do you need a computational biologist for sequence analysis?

Jefferson Parker, Ph.D., from NullSet Informatics Solutions
Read interview

What’s the benefit of AI/ML for structure-activity relationship studies?

Ben R. Taft, Ph.D., from Via Nova Therapeutics
Read interview

Learn more about how CAS can help you with your drug discovery efforts.

Learn about drug discovery